<DOC>
	<DOCNO>NCT01975389</DOCNO>
	<brief_summary>This study evaluate PCSK9 inhibitor , Bococizumab ( PF-04950615 ; RN316 ) , compare placebo , reduce occurrrence major cardiovascular event , include cardiovascular death , myocardial infarction , stroke , unstable angina require urgent revascularization high risk subject receive background lipid lower therapy cholesterol laboratory value LDL-C &gt; /= 100 mg/dL ( 2.6 mmol/L ) non-HDL-C &gt; /=130 mg/dL ( 3.4 mmol/L ) .</brief_summary>
	<brief_title>The Evaluation Bococizumab ( PF-04950615 ; RN316 ) Reducing Occurrence Major Cardiovascular Events High Risk Subjects</brief_title>
	<detailed_description>The trial terminate prematurely November 1 , 2016 , due emerge clinical profile evolve treatment market landscape lipid-lowering agent . These indicate bococizumab likely provide value patient , physician , shareholder . The decision base recommendation independent Data Monitoring Committee stop program .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Must background lipid lower treatment . Must high risk CV event . Must LDL C &gt; /=100 mg/dL ( 2.6 mmol/L ) OR non HDL C &gt; /=130 mg/dL ( 3.4 mmol/L ) . Planned coronary ( PCI CABG ) arterial revascularization . New York Heart Association Class IV congestive heart failure leave ventricular ejection fraction &lt; 25 % cardiac imaging . Chronic renal insufficiency creatinine clearance &lt; 30 ml/min/1.73m^2 MDRD formula end state renal disease dialysis . History hemorrhagic stroke . Prior exposure bococizumab investigational PCSK9 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>stroke</keyword>
	<keyword>hyperlipidemia</keyword>
</DOC>